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saccharide could maintain aqueous equilibrium between the dosage form and the surrounding med-
ium due to its massive competence of water absorption (80.72%) and swelling index (266.7%). The
Scanning Electron Micrograph of a polysaccharide exhibits rough surface with pores and crevices,
hence, the drug release will be retarded because of the drug particles entrapment in the pores and
crevices. Further, the surface tension of polysaccharide is higher than that of water, which may
facilitate sustained release of drugs from dosage forms. An antipsychotic drug, quetiapine fumarate
has a short half-life of 6 h and administered multiple times per day. Hence the quetiapine fumarate
oral sustained release tablets were formulated using this polysaccharide in the concentration of 5–
30% to avoid the side effects and increase patient compliance. Dissolution of the developed tablets
with 25% polysaccharide content showed a better release proﬁle than the other batches (5–20%) at
the end of 12 h. The strong matrix complex has low solubility in water, it does not dissolve rapidly
and the drug continues to diffuse through the gel layer at a consistent rate. Drug release from theess: Formulation & Develop-
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240 K. Krishnaraj et al.matrix tablets follows matrix type except F-4 and F-5 which follow ﬁrst order and Hix.crow type.
The bioavailability study was carried out using healthy male New Zealand white rabbits that show
the AUC(0–inf) value for developed SR tablets is 1.44 times higher than the reference thus, indicating
more efﬁcient and sustained drug delivery capable of maintaining plasma drug levels better.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Sustained release (SR) technology has rapidly emerged over
the past three decades as a new interdisciplinary science that
offers novel approaches to the delivery of bioactive agents into
systemic circulation at a predetermined rate. By developing a
predictable and reproducible drug release rate for an extended
period of time, SR formulations can achieve optimum thera-
peutic responses, prolonged efﬁcacy and decreased toxicity.
Hydrophilic matrix tablets are among the most popular
delivery systems for oral sustained release dosage forms
through the gastrointestinal (GI) route. This is largely because
they offer precise modulation of drug release as a result of
hydration of the constituent polymer(s), ﬂexibility to obtain
the desired drug release proﬁles, cost effectiveness, patient
compliance and providing a constant, prolonged, and uniform
therapeutic effect in blood levels of the drug unlike conven-
tional systems (Heng et al., 2001).
The use of hydrophilic polymers for sustained drug delivery
has attracted the attention of investigators in recent years.
Among the hydrophilic polymers, natural polysaccharides
are preferred due to their nontoxicity, biocompatibility, biode-
gradability and acceptance by the regulating agencies. Polysac-
charides, like cellulose ethers, xanthan gum, scleroglucan,
locust bean gum and guar gum, are some of the natural poly-
saccharides that have been evaluated in hydrophilic matrix
tablets for drug delivery systems (Tommasina et al., 2007).
Considerable research carried out on locust bean gum (Sujja
et al., 1998), guar gum (Krishnaiah et al., 2002), and tamarind
gum (Yamanaka et al., 2000) reveals that polysaccharides can
be isolated from their seeds or whole fruits. Delonix regia be-
longs to the same type containing the pod type fruits. It is a ﬂow-
ering plant from the Fabaceae family, noted for its fern-like
leaves and ﬂamboyant display of ﬂowers (Silvana et al., 2001).
It usually grows to a modest height (typically around 5 m,
though it can reach as high as 12 m) but spreads widely, and
its dense foliage provides full shade. Seed pods are dark brown
and can be up to 60 cm long and 5 cmwide; the individual seeds,
however, are small, weighing around 0.4 g on average. In India,
it is referred to asGulmohar. Sandra et al. (2003) have studied on
the three-dimensional structure of a novel Kunitz (STI) family
member an inhibitor puriﬁed from D. regia seeds. Generally,
its pods and seeds are considered as wastage and that too there
is no work that has been carried out related to polysaccharide
for sustained release formulation.
The aim of the present investigation is, therefore, to isolate
natural polysaccharide from the seeds ofD. regia and evaluate
it for sustaining release carrier, using quetiapine fumarate as a
model drug. The isolated polysaccharide named is as Gulmo-
har gum (GG) by authors for further reference.
Quetiapine fumarate (QF), 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-
yl-1-piperazinyl)ethoxy] ethanol fumarate, is an antipsychotic drug
belonging to a chemical class of dibenzothiazepine derivatives (Ihor
andLisa, 1997;Andrew et al., 2002). It is indicated for the treatmentof acute manic episodes associated with bipolar I disorder, both as
monotherapy and as an adjunct to lithium. It is also used for the
treatment of schizophrenia. Dyspnea, swelling of the face, lips, ton-
gue, or throat and sedation are the most common side effects and
other side effects are mood or behavior changes, anxiety, panic at-
tacks, aggressiveness, restlessness, hyperactivity, constipation, head-
ache, dry mouth and mild weight gain or weight loss (Diletti et al.,
1991). QF is well absorbed and extensively metabolised following
oral administration. It has a short half-life of 6 h and administered
orally 2–4 times a day. The frequency of dose administration leads
to increase in the risk of side effects and decrease in patient compli-
ance.Thoughpatient compliance is bestwithone dose daily, the risk
of schizophrenia recurrence aftermissing adosemayalsobe further-
most. The sustained release QFmay effective serum levels for 24 h,
and therefore, missing a dose could result insufﬁcient therapeutic
cover for many hours. Other reason for developing a QF sustained
release formulation is to allowing use of longer dosing intervals. In
addition, this regimenmaybe relatedwith subtlepsychological assis-
tances, particularly for those patients who are schizophrenia or
manic-free and recognize each dose taking act as an obnoxious
remainder of their disease. Thus the development of QF SR formu-
lation is required.
2. Materials and methods
Gulmohar seeds were collected in Kumbakonam, Middle East-
ern part of Tamilnadu, India. Quetiapine fumarate (QF) was
procured from Beijing Lunarsun Pharmaceutical Co., Ltd.,
China. PVP-K-30 (Poly vinyl pyrolidine from ISP) was a gift
sample from Anshul agencies, Mumbai. Starch 1500 was a gift
sample from Colorcon, India. Aerosil (colloidal silicon diox-
ide) was purchased from Degussa, Mumbai. All the reagents
and chemicals used for analytical development were of HPLC
grade.
2.1. Isolation of the polysaccharide GG
Gulmohar seeds (100 g) were soaked in 800 ml of warm water
for 24 h. The water was discarded and the seeds were immersed
in 800 ml of fresh boiling water for 4–5 h. The seeds were then
removed from water, washed and the tegument broken and
separated manually from the seed coat. The thick transparent
cotyledon portion was separated from the seed coat and the
embryonic axis. The cotyledon portions were milled and
squeezed using several folds of muslin cloth to separate the
marc from the ﬁltrate. Absolute alcohol was then added to
the ﬁltrate to precipitate the polysaccharide. The polysaccha-
ride was separated by ﬁltration and dried in an oven at
60 C until constant weight. The dried polysaccharide ﬁlm
was milled and sifted with an 80 mesh sieve to obtain the ﬂour
(GG). The crude polysaccharide was puriﬁed through barium
complexing by preparing 2.5% (w/v) solution of the gum by
continuous stirring for 12 h at 60 C and precipitating with sat-
urated barium hydroxide solution. The complex was separated
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centrifuged and precipitated with absolute alcohol. It was
washed with absolute alcohol for 4–5 times. The sample was
ﬁnally puriﬁed by dialysis and ﬁltration through various Milli-
pore membranes (0.65 lm and 0.45 lm).
2.2. Evaluation of the polysaccharide
Phytochemical screening was carried out to check the polysac-
charide purity (Evans et al., 1996). The physicochemical prop-
erties were analyzed according to the Indian Pharmacopoeia
(1996). The pH of 1% aqueous solution was determined using
a digital pH meter. Color and clarity were determined by dis-
solving 100 mg of the polysaccharide in carbon dioxide free
water and checking for its clarity against a dark background.
Surface tension was determined by the drop count method
using a stalagmometer. Carr’s index, water absorption study
and swelling index (Alka et al., 1995) have also been carried
out.
2.3. Toxicity studies
2.3.1. Acute oral toxicity study of the polysaccharide
The polysaccharide was tested for acute oral toxicity in female
Wistar rats as per the OECD guideline for the testing of chem-
icals, ‘‘Acute Oral Toxicity Study (UP and DOWN Method)’’,
Guideline No. 425. The test was carried out by using ﬁve fe-
male rats (one animal per step) with a starting dose of
175 mg/kg and it was tested up to 2000 mg/kg b.wt. dose.
The test item was prepared as a solution in water and admin-
istered as a single oral dose to overnight fasted (16–18 h) rats
at the dose volume of 10 ml/kg b.wt. Mortality, clinical obser-
vations, body weights and gross necropsy ﬁndings were
evaluated.
2.3.2. Repeated dose (28 day) oral toxicity study
of the polysaccharide
The polysaccharide was tested for its toxic effects in a 28 day
oral toxicity study in Wistar rats. The test item was prepared
as a solution in water and administered by oral gavage at doses
of 10, 50, and 100, mg/kg b.wt. to G2, G3 and G4 groups of
rats, respectively. The concurrent control group (G1) received
water without the test item. All the groups consisted of 5 male
and 5 female rats. Animals from all the groups were observed
for clinical signs, physical abnormalities, changes in body
weight and pre-terminal deaths. Laboratory investigations
such as hematology and clinical chemistry were performed at
sacriﬁce and the data were statistically analyzed. The rats were
subjected to detailed necropsy at terminal sacriﬁce.Table 1 Tablet composition (% w/w) of different batches of QF SR
Batch No. QF GG Starch 1500
F-1 40 5 48.5
F-2 40 10 43.5
F-3 40 15 38.5
F-4 40 20 33.5
F-5 40 25 28.5
F-6 40 30 23.52.4. Compatibility study
The drug, the polysaccharide and the optimized formulation
were subjected to Differential Scanning Calorimetry (DSC)
using a Perkin Elmer SERIES DSC7, United Kingdom. Accu-
rately weighed samples (3–7 mg) were hermetically sealed in
ﬂat bottomed aluminum pans and heated from 50 to 360 C
at a rate of 20 C per min in an atmosphere of nitrogen. The
thermograms were normalized. FTIR studies were also per-
formed on the drug, the polysaccharide and the optimized for-
mulation using FTIR Shimadzu., Japan.
2.5. Development of SR tablets, evaluation and in vitro
drug release studies
Six batches of QF SR tablets were prepared according to the
composition shown in Table 1 corresponding to different GG
concentrations of 5%, 10%, 15%, 20%, 25%, and 30% , coded
as, F-1, 2, 3, 4, 5 and 6 respectively. Drug with and without the
diluents was deagglomerated using the British Standard Sieve
(BSS) with 0.25 mm opening. The premix and the polysaccha-
ride were granulated using PVP-K-30 in isopropyl alcohol as
the granulating ﬂuid. The wet mass was passed manually
through BSSwith 1.7 mm opening. The granulations were dried
at 60 C for 2 h until the loss on drying of the granules was be-
tween 1% and 2%w/w. The dried granules were passed through
BSS 1.0 mm and evaluated for ﬂow properties and compress-
ibility index (Banker and Anderson, 1987). The granules were
blended with magnesium stearate and aerosil. The blends were
compressed using 12 mm ﬂat punches on a rotary tablet press.
The thickness of the tablets was determined using a thickness
gauge (Mitutoyo, New Delhi, India). Weight variation was re-
corded using an electronic balance (Sartorius India limited, In-
dia). The hardness and friability were determined using the
Monsanto hardness tester (Cadmach, Ahmedabad, India) and
the Roche friabilator (Electrolab,Mumbai, India), respectively.
Drug content of the tablets was also determined by using 20 tab-
lets. The in vitro dissolution studies of the developed SR tablets
and immediate release (IR) tablets were carried out using USP
type II apparatus (Electrolab, Mumbai, India) at 50 rpm. The
dissolution medium consisted of 900 ml of pH 6.8 phosphate
buffer solution, maintained at 37 ± 0.5 C. The drug release
at different time intervals was measured. The release studies
were conducted in triplicate for each batch. These release stud-
ies were compared with IR tablets too.
2.5.1. Kinetics and mechanism of drug release
The in vitro release proﬁles were ﬁtted to Peppas, Hixon–Cro-
well, Higuchi and zero-order equations (Eqs. ())(1)–(4),tablets.
PVP-K-29/32 Magnesium stearate Aerosil
5 1 0.5
5 1 0.5
5 1 0.5
5 1 0.5
5 1 0.5
5 1 0.5
242 K. Krishnaraj et al.respectively) by using the least square method of analysis to
understand the mechanism of in vitro drug release and to com-
pare the release proﬁle differences among these matrix
formulations.
Mt=M1 ¼ Ktn ð1Þ
Mt=M1 ¼ 1 ð1 k1tÞ3 ð2Þ
Mt=M1 ¼ bþ k2t1=2 ð3Þ
Mt=M1 ¼ aþ k3t ð4Þ
In Peppas equation,Mt/M1 (Korsmeyer et al., 1983) is the
fraction of drug released up to time t, K is the kinetic constant
and n is the release exponent indicative of the release mecha-
nism. In Hixon–Crowell (Hixson and Crowell, 1931), Higuchi
(1963) and zero-order (Gibaldi and Feldman, 1967) release
equations, k1, k2 and k3 are constants. The Hixon–Crowell
equation indicates an erosion dependent release mechanism.
On the other hand, the Higuchi equation expresses a diffuse re-
lease mechanism. The results were analyzed by one way anal-
ysis of variance.
2.6. Stability study
Stability studies were carried out as per ICH (Q1A (R2), 2003)
guidelines. The optimized matrix tablets were packed in screw
capped high density polyethylene containers and isothermally
stressed to study the stability under accelerated temperature
and relative humidity (RH) conditions (40 C and 75% RH)
in stability chambers (Thermo lab, Mumbai, India) for
3 months. Test samples were withdrawn every month and sub-
jected to various tests, including visual inspection for any
appreciable change on the tablet surface, assay, hardness, fria-
bility and dissolution. F2 (similarity factor) values were calcu-
lated to verify the similarity of the dissolution proﬁles. FT-IR
spectroscopy and differential scanning calorimetry were used
to characterize the stability of the formulations.
2.7. Bioavailability studies of the optimized formulation
in New Zealand white rabbits
The male New Zealand white rabbits were given access to nor-
mal standard diet and tap water ad libitum, during the experi-
ment. The animals were housed, two per cage in standard
rabbit cages maintained at 22 ± 3 C under a 12 h light and
12 h dark cycle. The animals were acclimatized at least oneTable 2 Physicochemical properties of the isolated polysaccharide.
Parameter Observation P
Color and clarity Colorless and clear B
pH 6.58 C
Loss on drying (% w/w) 2.58 A
Total ash (% w/w) 0.50 S
Acid insoluble ash (% w/w) 0.03 T
W
Water soluble ash (% w/w) 0.24 S
Solubility Slowly soluble in cold water and quick
practically insoluble in organic solventweek prior to the start of the experiment. Rabbits were divided
into two groups of six animals each. The weight of the rabbits
ranged from 1.5 to 2 kg. The rabbits were fasted for at least
24 h prior to the experiments and were given free access to
water. The study was carried out in a cross over design with
a wash out period of 7 days between the two dosing. During
the ﬁrst phase, the animals received either the reference prod-
uct (20 mg of standard QF in distilled water) or the test prod-
uct (20 mg of QF SR tablets). In the second phase, the rabbits
which received the test product were administered with the ref-
erence product and vice versa. The reference product was
administered by distilled water orally through a catheter.
Blood samples (2 ml) were withdrawn from the marginal ear
vein at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 24 h after the oral
administration of the test/reference products to each of the
rabbits. The blood samples were centrifuged at 3500 rpm for
5 min. The plasma samples (0.5 ml) were stored at 70 C until
analyzed by the HPLC. Maximum plasma concentration
(Cmax) and time to reach the same (Tmax) after oral administra-
tion were determined from the plasma concentration values.
The measured plasma concentrations served to calculate the
area under the plasma concentration–time curve from time
zero to the last concentration time point (AUC0–t) and the area
under the plasma concentration–time curve from time zero to
inﬁnity (AUC0–inf). AUC0–t was calculated according to the
trapezoidal rule. AUC0–inf was calculated by the sum of
AUC0–t and the last measured concentration divided by the
elimination constant (Ct/keli). The relative bioavailability of
the optimized once daily SR tablets of F-5 was compared with
the reference QF in healthy rabbits. The results were analyzed
by unpaired Student ‘t’ test. In addition, the 95% conﬁdence
level is considered for testing. Each test animal was compared
with the reference individually at the respective time point.
3. Results
3.1. Characterization of the polysaccharide
The physicochemical properties of polysaccharide are shown
in Table 2. The angle of repose data reveals that GG has good
ﬂow properties. The pH of GG in solution form is close to neu-
tral. This indicates GG may not cause any irritation to the epi-
thelium and mucous membrane in the GI tract. The water
absorption and swelling index of GG are high. GG can, there-
fore, maintain the aqueous equilibrium between the dosage
form and the surrounding medium. The Scanning Electron
Micrograph (SEM) of GG is shown in Fig. 1. The micrographarameter Observation
ulk density (g/ml) 0.57
arr’s index 28.6
ngle of repose 28560
urface tension (dynes/cm) 98.23
rue density (g/cc) 1.162
ater absorption (%) 80.72
welling index (%) 266.7
ly soluble in hot water; forms a viscous colloidal solution;
s
Figure 2 Compatibility studies. DSC thermogram of: (A)
quetiapine fumarate, (B) Gulmohar gum, (C) formulation.
Figure 1 SEM of Gulmohar gum.
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drug release from the dosage forms depends on the surface
characteristics of excipients. If the surface is rough, drug re-
lease will be retarded because of the entrapment of drug parti-
cles in the pores and crevices. Further, the surface tension of
GG is higher than that of water, which may facilitate sustained
release of drugs from dosage forms. Based on the physico-
chemical studies, GG could be used as a pharmaceutical
excipient.
3.2. Toxicity studies
3.2.1. Acute oral toxicity study on GG in Wistar rats
No deaths and signiﬁcant body weight changes or gross nec-
ropsy ﬁndings during the study. Based on the results of the
acute oral toxicity on the polysaccharide in Wistar rats, it
may be concluded that the LD50 of the test item is greater than
2000 mg/kg.
3.2.2. Repeated dose (28 day) oral toxicity study on GG
in Wistar rats
The results of the study indicate that GG has no adverse effects
on the general health, growth, organ weight ratios, hematolog-
ical and clinical chemistry parameters, at a dose of 100-mg/kg
b.wt. The results obtained indicate that No Observed Adverse
Effect Level (NOAEL) in Wistar rats is 100 mg/kg b.wt. under
the testing conditions employed. The results of acute and re-
peated oral toxicity studies revealed that the polysaccharide
does not have any toxic properties and can be used for oral
administrations.
3.3. Compatibility studies of QF with GG
The IR spectrum shows a sharp peak at 3317 cm1 for QF indi-
cating the presence of free OH group. The peaks at 1305 and
1130 cm1 show the presence of aromatic C–N andC–S, respec-
tively. The presence of aliphatic chain and aromatic C–C groups
are indicated by the peak at 3074 and 1599 cm1, respectively.
All these groups are seen in the formulation also. The formula-
tion does not contain any new peaks. The DSC thermograms of
the formulation also show the characteristic endothermic peakof the QF at 177 C (Fig. 2). The studies thus reveal no interac-
tions between the GG and the drug. The polysaccharide, GG,
and the drug are thus compatible with each other.
Based on the physicochemical, toxicity and compatibility
studies GG was selected as a carrier for developing SR tablets.
3.4. Physical evaluation of the granules and tablets
The optimized granules:ﬁnes ratio was 60:40. The granule prop-
erties of the different QF SR batches are shown in Table 3. The
data reveal that all the batches are having moderate to good
Figure 3 In vitro release of quetiapine fumarate tablets (n= 3)
in pH 6.8 phosphate buffer solution at 50 rpm: (a) batches from F-
1 to F-3 and immediate release tablets, (b) batches of F-4 to F-6
and immediate release tablets.
244 K. Krishnaraj et al.ﬂow capacity, LBD and TBD. These properties were assisted to
uniform ﬁll weight and avoided some problems during the tab-
let compression. Each batch shows limited moisture content
and good Carr’s index. Hence, all the batches were containing
uniform drug content and hardness of the tablets. The tablet
characteristics of the different batches are shown in Table 4.
It is observed that the friability values decrease as the polysac-
charide concentration increases. All the batches are uniform
in thickness with respect to hardness. Optimum tablet hardness
has beenmaintained by compression force and thickness, hence,
the tablets have enough strength for shipping. All the physical
parameters of the tablets are thus found to be practically within
controls. The concentration of the polysaccharide does not ex-
hibit any effect on the drug content of different batches.
3.5. In vitro dissolution studies and kinetic mechanism
Six different batches F-1 to F-6 were prepared and the in vitro
release results are shown in Fig. 3a and b. The data reveal that
the concentration of polysaccharide has a signiﬁcant impact
on the drug release. Drug released from all the batches was
nearly equivalent up to 1 h except in the case of IR tablets.
However the drug release that differs at 2 h (Fig. 4) from all
the batches is between 21% and 39%. The drug release de-
creases when the GG concentrations have increased. In the
case of IR tablets, they disintegrated rapidly and QF dissolves
in the medium very soon. Almost, 95% of QF release has oc-
curred within 1 h. The drug release from the batches with 25%
and 30% polysaccharide content was comparatively slower
than tablets with 5–20% polysaccharide content (F-1 to F-4).
The dissolution for the ﬁrst 12 h period for the F-5 batch tab-
lets is steady till the polymer relaxation becomes predominant
(Fig. 4).
The release data were ﬁtted to different kinetic models to
determine the mechanism of drug release. Zero order, ﬁrstTable 3 Granulesa properties of different QF SR batches.
Batch No. Angle of repose LBDb TBDc
F-1 30230 0.32 ± 0.00 0.41 ± 0.0
F-2 31520 0.33 ± 0.00 0.41 ± 0.0
F-3 34440 0.30 ± 0.00 0.42 ± 0.0
F-4 30360 0.32 ± 0.00 0.43 ± 0.0
F-5 29540 0.34 ± 0.01 0.42 ± 0.0
F-6 33130 0.31 ± 0.00 0.38 ± 0.0
a The values represent mean ± SD (n= 6).
b Loose bulk density.
c Tapped bulk density.
Table 4 Tablet characteristics of the different batches of QF SR ta
B. No Thicknessa (mm) Hardnessa (kg/cm
F-1 3.93 ± 0.05 5.5 ± 0.21
F-2 3.97 ± 0.04 5.4 ± 0.29
F-3 3.94 ± 0.02 5.6 ± 0.32
F-4 3.98 ± 0.03 5.5 ± 0.48
F-5 3.95 ± 0.05 5.4 ± 0.18
F-6 3.92 ± 0.04 5.3 ± 0.47
a n= 10.
b n= 20.order, Higuchi, Hixon–Crowell and Korsmeyer–Peppas are
the major models to identify the drug release from sustained
release formulations. The kinetics of drug release of QF fromCarr’s index Hausner ratio Moisture content
0 20.93 1.26 1.56
1 20.96 1.27 1.29
1 27.24 1.37 1.47
1 25.66 1.35 1.44
0 18.92 1.23 1.26
1 17.63 1.21 1.87
blets.
3) Friabilityb (%) Drug contentb (%)
0.46 99.21
0.44 98.57
0.39 97.48
0.39 97.34
0.33 98.51
0.30 98.24
Figure 4 Comparitive drug release studies of F-1 to F-6 tablets
with immediate release tablets at 2 h and 12 h.
Figure 5 Higuchi plot for F-5 batch tablets.
Figure 6 Peppas plot for F-5 batch tablets.
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sion coefﬁcients and release rate constant values were consid-
ered for ﬁtting. The data reveal that the drug release from
GG matrix tablets follow matrix type except F-4 and F-5
which follow ﬁrst order and Hix.crow type. The release mech-
anism of F-5 tablets is primarily by diffusion of the dissolved
QF across the gel layer. At the end of 12 h dissolution the tab-
lets formulated with 25% polysaccharide content (F-5) showed
a better release proﬁle than the other formulations (Fig. 4). F-5
was, therefore, selected for evaluation of stability and bioavail-
ability studies.
3.6. Stability studies
The results of the stability studies of the selected batch, F-5,
are shown in Table 6. The accelerated stability studies indicate
that the developed SR tablets are unaffected after 3 months
storage under accelerated conditions as no changes are ob-
served in the differential scanning calorimetric thermograms.
Moreover, no signs of visually distinguishable changes are ob-
served in the appearance, texture and color of the formulation.
The data on drug content and friability are comparable with
those of the control samples and are within the limits. F2 val-
ues of 50–100 indicate similarity between the dissolution pro-
ﬁles. On the basis of these results, it may be concluded that
the optimized formulation developed is stable under acceler-
ated conditions for 3 months.
3.7. Pharmacokinetic evaluation
The results of the mean pharmacokinetic proﬁles calculated for
the developed SR tablets and the reference QF are presented inTable 5 Kinetic release rate of the different batches of developed Q
S. No. Batch No. Zero order First order Matrix
R k R k R k
1. F-1 0.9590 3.8208 0.9922 0.1063 0.9941 1
2. F-2 0.7847 5.1228 0.9598 0.1304 0.9966 2
3. F-3 0.9501 4.1748 0.9878 0.1213 0.9901 2
4. F-4 0.9564 4.3864 0.9967 0.1101 0.9946 2
5. F-5 0.9720 5.2147 0.9849 0.1532 0.9981 2
6. F-6 0.9826 4.7991 0.9775 0.1371 0.9979 2Table 7 and Fig. 7. The results show very rapid drug absorption
from the reference as revealed by a Tmax of 4.83 ± 1.03 h as
compared to a Tmax of 7.33 ± 0.98 QF for SR tablets. The
developed SR tablets gave a plasma concentration–time proﬁle
typical of the prolonged dissolution characteristic of an SR for-
mulation. The developed F-5 thus demonstrates a longer time to
reach the peak concentration than the reference and appear to
be more consistent in its overall performance as indicated by
a lower variation in plasma concentrations, longer time to peak
and lower peak plasma concentration. The data obtained fur-
ther reveal the absence of a burst-effect in F-5 in fasted, healthy
animals. There is signiﬁcant difference in the extent of absorp-
tion as seen from the AUC0–24 values. However, the AUC0–inf
value for SR tablets is 1.44 times higher than the reference thus,
indicating more efﬁcient and sustained drug delivery capable of
maintaining plasma drug levels better. This is also evident fromF sustained release tablets.
Peppas Hix.crow Korsmeyer–Peppas
R k R k n
9.433 0.9907 26.0050 0.9921 0.0245 0.4373
0.322 0.9961 21.8069 0.9719 0.0292 0.4695
1.346 0.9801 22.2364 0.9896 0.0273 0.5211
2.383 0.9885 18.0344 0.9901 0.0263 0.5933
6.273 0.9934 11.9937 0.9987 0.0337 0.7741
3.912 0.9957 15.1737 0.9954 0.0307 0.6474
Table 6 Tablet properties of the developed F-5 SR tablets during stability studies.
Parameter Initial 1st month 2nd month 3rd month
Controla Acceleratedb Controla Acceleratedb Controla Acceleratedb
DSC (transition temperature) 177.28 177.74 177.59 – – 176.48 175.62
Thickness (mm) 3.95 ± 0.05 3.93 ± 0.03 3.89 ± 0.04 3.93 ± 0.04 3.93 ± 0.03 3.81 ± 0.03 3.90 ± 0.04
Hardness (kg/cm3) 5.1 ± 0.22 5.4 ± 0.42 5.5 ± 0.53 5.4 ± 0.41 5.5 ± 0.35 5.4 ± 0.42 5.3 ± 0.44
Friability (%) 0.36 0.12 0.14 0.16 0.24 0.36 0.44
Drug content (%) 99.42 99.40 ± 0.54 99.06 ± 0.34 98.62 ± 0.28 97.22 ± 0.24 98.46 ± 0.82 96.42 ± 0.46
F2 value
c (similarity factor) – 96.46 94.64 95.72 86.04 90.52 81.47
a Control samples were stored at 22 ± 2 C and 45 ± 5% RH.
b Samples were stored at 40 ± 2 C and 75 ± 5% RH.
c F2 values of 50–100 indicates similarity between the dissolution proﬁles.
Table 7 Pharmacokinetic parameters (n= 12) of the developed F-5 tablets and standard QF in healthy animals.
Pharmacokinetic parameters Standard QF Developed SR tablet
Cmax (ng/ml) 229.57 ± 9.37 186.32 ± 4.21
Tmax (h) 4.83 ± 1.03 7.33 ± 0.98
AUC(0–24) (ng h/ml) 2126.02 ± 326.71 2706.19 ± 165.25
keli (h
1) 0.13 ± 0.04 0.08 ± 0.01
t½ (h) 5.76 ± 0.99 9.02 ± 0.65
AUC(0–1) (ng h/ml) 2339.10 ± 370.17 3374.95 ± 209.76
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values (9.02 ± 0.65) for QF SR tablets. The drug release from
the GG is thus sustained and could maintain the drug level in
blood plasma. The in vivo concentration–time proﬁle thus
shows that the tablets maintain their integrity while traversing
the stomach. There was a statistically signiﬁcant (P< 0.0001)
difference that occurred at the time of 1 h and continued to be
signiﬁcant up to 24 h when compared to reference.
4. Discussion
The major difﬁculties of novel isolated polymers (from the
plant parts) are physical appearance and impurities. The phys-
ical appearance of seed polysaccharides like tamarind, locust
bean and guar are dull brown in color. This is due to their seed
cover and other seed parts color that might drain and stain the
polysaccharides during the extraction process. But, the cotyle-
don portion of the GG seeds is very thick and transparent (no
stain) even after being boiled. Hence the process of cotyledon
portion isolation was easy and gave high quantity of the yield.
The transparent white color favors the appearance of the tablet
too. The impurities of the polysaccharide might offer brown or
black colored spots on the tablet that appear awful. Impurities
are also involved in the tablet sustained release properties.
They absorb the dissolution medium rapidly and dissolve
soon. These dissolved portions act as channels. The surround-
ing medium could enter into the tablet core via these channels
easily, therefore, the tablet gets disintegrate rapidly. Thus, the
sustained release could not be achieved. Unlike this, the thick
and transparent isolated cotyledon portion of GG seeds could
be washed easily hence there was the absence of impurities and
color of the GG. The GG did not have any toxicity and is suit-
able for the pharmaceutical application. It is stable in all the
conditions individually as well as with the excipients. The gran-
ules’ properties show that GG envelops QF uniformly and theblending was done properly, hence, the drug content of each
batch is uniform and under the limit. All the granules’ param-
eters are under acceptable limits. The prepared tablets are in
uniform thickness and hardness. This is due to physicochemi-
cal characters of the GG and the uniform mixing of the tablet
blend.
The dissolution method development has done using differ-
ent pH buffer solutions and different paddle speeds. Finally,
pH 6.8 phosphate buffer solution with 50 rpm was selected.
The tablet(s) were settled down as soon as they put into the
dissolution medium and remained at the bottom of the basket.
This shows that the prepared tablets are not having any air
entrapment. Further, the tablets did not liberate any air bubble
in the dissolution medium during the entire study. GG did not
react with the other excipients, hence, it does not liberate the
gas. If GG contains any gas, the tablet may ﬂoat on the disso-
lution medium. The tablets did not ﬂoat at the center of the
basket during dissolution studies too. This is due to higher sur-
face tension than water and limited density of GG. The disso-
lution studies show that the drug dissolves nearly up to 1.5 h
due to the possibility of the surface of the tablets containing
free QF. The soluble nature of QF in dissolution medium is
also another causative. Hence, in Fig. 3a and b show a super-
imposed graph up to 1.5 h. After 1.5 h or from 2 h onward the
GG forms a gel layer. At 2 h the QF release from F-1 to F-6 is
39.01%, 36.22%, 31.41%, 30.77%, 26.89% and 21.53%
respectively (Fig. 4). At this point, the drug release increases
when the polymer concentration decreases. The rough surface
with pores and crevices of the GG forms a strong matrix and
retains the drug prolongation. Increasing the concentration of
the GG decreases the size of the matrix channels that leads to
increases in the degree swelling. The nature of starch 1500 in
water and the gel forming capacity of GG could be other rea-
sons for the drug release retardant. The strong matrix can form
between GG and starch 1500. This hydrogel matrix had low
Figure 7 Plasma concentration–time proﬁle of quetiapine fuma-
rate (n= 12) from developed F-5 tablets and reference tablets.
Statistically signiﬁcant (P< 0.0001) difference occurred at the
time of 1 h and continues to be signiﬁcant up to 24 h when
compared to the reference.
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tinues to diffuse through the gel layer at a uniform rate. But at
12 h the QF release from F-1 to F-6 is 77.62, 78.52, 79.41,
76.38, 72.84 and 74.99 respectively (Fig. 4). There is not much
difference in drug release (%) from all the batches. This is due
to prolonged duration of tablets in dissolution medium that
may enhance the channel opening wide and increase the solu-
bility of the excipients. When compared to all other batches F-
5’s release pattern was good and close to expected results. Un-
like xanthan gum, GG is not pH dependable. Xanthan gum,
an ionic polymer is a naturally available sustained release
agent. Its matrix has been slower at lower pH values (Billa
and Yuen, 2000). When the dissolution takes place it swells
and the outer layer of the tablets appeared to be hydrated. A
progressive boost in the size of these hydrates, is particularly
visualized for matrices’ steady loss of integrity, resulting from
the hydrodynamic stress induced by the dissolution apparatus
(Ueberreiter, 1967).
The kinetic data reveal that QF release from GG matrix
tablets follow matrix type except F-4 and F-5 which follow ﬁrst
order and Hix.crow type. Mechanism of these matrices swells
politely and may hold the drug in the gel layer. It is likely that
as the concentration of the drug becomes high within the gel
matrix and its thermodynamic activity or chemical potential
increases, the gel layer around the tablet core actually acts al-
most like a rate-controlling membrane resulting in linear drug
release. The kinetic release mechanism of F-5 indicates the re-
lease might be the dissolution of the QF initially rapid due to
free QF at the surface of the tablets and the matrix absorbed
water started swelling gradually. As the dissolution progressed,
the gradual swelling of the outer layer created proportionally
new areas for the QF diffusion. Since the matrix was hydro-
philic, the permeation of dissolution medium in the matrix
had taken place and it initiated dissolution of the QF from
the inner layers. The balance between swelling and gelling
characteristics of the matrix system was maintaining the de-
sired QF release rate.
The pharmacokinetic proﬁle for the developed SR tablets
has given the expected sustained release result as that of the
dissolution studies. SR tablets started sustained release action
after ingestion when compared to the IR tablets. The promptsustained release has occurred up to 3 h. This may not be
due to the acidic medium. This is because of the free QF pres-
ent on tablet surface (like that of the dissolution results). The
release from F-5 could be rapid if the GG is pH dependent or
acid soluble. Expectedly, the release pattern of SR tablets is
sustained. The drug release might be slower after 3 h when
compared to the initial. The QF release of SR is slow and stea-
dy up to 24 h. The IR tablets may disintegrate rapidly and get
absorbed. The high elimination constant has occurred com-
pared to SR tablets. This is suggesting that the gel is strong en-
ough to resist the powerful peristaltic contractions that
normally occur in the fasted state which opens the pylorus
and clears the stomach of any residual material. The Tmax of
SR tablets is comparatively longer than the IR tablets. This
is also an evidence for the prolonged action of developed SR
tablets. Hence the GG has SR properties and is not a pH
dependent polymer. From the environmental aspect, an agri-
cultural waste, GG seeds are used as a source of valuable mate-
rials of commercial pharmaceutical importance.
5. Conclusion
An isolated polysaccharide from the seeds of D. regia exhibits
good physicochemical properties and does not have toxicity. In
vitro drug release studies of the developed F-5 batch SR tablets
reveal that drug release takes place slowly up to 24 h period
and is ﬁtted into the Hixon–Crowell kinetic mechanism. Drug
absorption from the developed SR tablets is higher when com-
pared to the reference drug in healthy rabbits thus indicating
that they maintain drug–plasma levels. There is no difference
in the AUC values between the formulation and the reference
drug and no signiﬁcant difference in their absorption was
found thus indicating the complete absorption of QF. The iso-
lated polysaccharide, GG from Gulmohar gum can, therefore,
be used as a carrier for developing sustained release formula-
tions (Fig. 7).Acknowledgements
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